Skip to main content
. 2012 Feb 14;20(5):927–937. doi: 10.1038/mt.2012.10

Figure 5.

Figure 5

Treatment of established CT26 tumors with adenovirus expressing scIL-12-B7TM. (a) 3T3 cells were infected with Ad/scIL-12-B7TM or Ad/scIL-12 at 100 multiplicity of infection for 48 hours, then the cells were stained with anti-mouse IL-12 p40/p70 mAb (solid lines) or an isotype control mAb (dashed lines) and analyzed by flow cytometry. (b) Groups of BALB/c mice (n = 8–12) were injected subcutaneously with 5 × 105 CT26 cells, then treated with 1 × 109 pfu of Ad/scIL-12-B7TM, Ad/scIL-12, or Ad/GFP on days 10 and 14 by intratumoral injection, and tumor growth was measured. (c) Groups of BALB/c mice (n = 5) were injected subcutaneously with 5 × 105 CT26 cells in the right flank, and 1 × 105 CT26 cells in the left flank. The right flank tumor were treated with 1 × 109 pfu of Ad/scIL-12-B7TM, Ad/scIL-12, or Ad/GFP as described above, and the left flank tumor remained untreated. Tumor growth was monitored at the indicated times, and the results are presented as the mean ± SD. IL, interleukin; mAb, monoclonal antibody.